309 related articles for article (PubMed ID: 14585225)
1. New therapeutic strategies for soft tissue sarcomas.
von Mehren M
Curr Treat Options Oncol; 2003 Dec; 4(6):441-51. PubMed ID: 14585225
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
3. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
Kopp HG; Patel S; Brücher B; Hartmann JT
Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.
Hartmann JT; Patel S
Drugs; 2005; 65(2):167-78. PubMed ID: 15631540
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Hartmann JT
Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
Schöffski P; Dumez H; Wolter P; Stefan C; Wozniak A; Jimeno J; Van Oosterom AT
Expert Opin Pharmacother; 2008 Jun; 9(9):1609-18. PubMed ID: 18518789
[TBL] [Abstract][Full Text] [Related]
7. Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
Patel SR
Expert Opin Investig Drugs; 2002 Dec; 11(12):1789-93. PubMed ID: 12457438
[TBL] [Abstract][Full Text] [Related]
8. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.
Mita MM; Gong J; Chawla SP
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829
[TBL] [Abstract][Full Text] [Related]
9. Systemic management strategies for metastatic soft tissue sarcoma.
Movva S; Verschraegen C
Drugs; 2011 Nov; 71(16):2115-29. PubMed ID: 22035513
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Ratan R; Patel SR
Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249
[TBL] [Abstract][Full Text] [Related]
11. Role of new chemotherapy agents in soft tissue sarcoma.
von Mehren M
J Natl Compr Canc Netw; 2005 Mar; 3(2):198-205. PubMed ID: 19817029
[TBL] [Abstract][Full Text] [Related]
12. [Perspectives on the oncologist pharmacopoeia].
Lansiaux A; Bailly C
Bull Cancer; 2003 Jan; 90(1):25-30. PubMed ID: 12609801
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin for the treatment of soft tissue sarcomas.
De Sanctis R; Marrari A; Santoro A
Expert Opin Pharmacother; 2016 Aug; 17(11):1569-77. PubMed ID: 27328277
[TBL] [Abstract][Full Text] [Related]
14. The evolution of systemic therapy in sarcoma.
Constantinidou A; Pollack S; Loggers E; Rodler E; Jones RL
Expert Rev Anticancer Ther; 2013 Feb; 13(2):211-23. PubMed ID: 23406562
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of ET-743: the French experience.
Brain EG
Anticancer Drugs; 2002 May; 13 Suppl 1():S11-4. PubMed ID: 12173489
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.
Mahmood ST; Agresta S; Vigil CE; Zhao X; Han G; D'Amato G; Calitri CE; Dean M; Garrett C; Schell MJ; Antonia S; Chiappori A
Int J Cancer; 2011 Oct; 129(8):1963-9. PubMed ID: 21154746
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin therapy for sarcomas.
Casali PG; Sanfilippo R; D'Incalci M
Curr Opin Oncol; 2010 Jul; 22(4):342-6. PubMed ID: 20489618
[TBL] [Abstract][Full Text] [Related]
19. New targeted agents in gastroenteropancreatic neuroendocrine tumors.
Benavent M; de Miguel MJ; Garcia-Carbonero R
Target Oncol; 2012 Jun; 7(2):99-106. PubMed ID: 22585431
[TBL] [Abstract][Full Text] [Related]
20. [Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment].
Bay JO; Cabrespine A; Gilliot O; Bailly C; Vincent C; Mishellany F; Gimbergues P
Bull Cancer; 2007; 94 Spec No Actualites():S122-6. PubMed ID: 17845981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
